section name header

Evidence summaries

Preoperative Chemotherapy in Esophageal Carcinoma

Preoperative chemotherapy may plus surgery offers some advantage in survival compared to surgery alone for resectable thoracic esophageal cancer. Level of evidence: "C"

A Cochrane review [Abstract] 1 included 13 studies with a total of 2 362 subjects. Ten trials (2 122 patients) were included in a meta-analysis for the primary outcome. There was some evidence that preoperative chemotherapy improves survival (HR 0.88; 95% CI 0.80 to 0.96) and is associated with a significantly higher rate of complete (R0) resection (RR 1.11, 95% CI 1.03 to 1.19). There was no evidence that the overall rate of resections (RR 0.96, 95% CI 0.92 to 1.01), tumour recurrence (RR 0.81, 95% CI 0.54 to 1.22) or non-fatal complication rates (RR 0.90; 95% CI 0.76 to 1.06) differ for preoperative chemotherapy compared to surgery alone. Trials reported risks of toxicity with chemotherapy that ranged from 11% to 90%.

Comment: The quality of evidence is downgraded by inconsistency (variability in results across studies) and by indirectness (differences in studied patients).

    References

    • Kidane B, Coughlin S, Vogt K et al. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 2015;5():CD001556. [PubMed]

Primary/Secondary Keywords